Contact information
Research groups
Gusztav Milotay
DPhil Student
Prior to starting a DPhil, I worked in a TCR therapeutics company called Etcembly where I contributed to the development of a microfluidics platform for peripheral immune repertoire sequencing. I am now looking to expand on single cell approaches to try and deorphanise TCRs in melanoma patients who respond to checkpoint immunotherapy and potentially leverage this to probe the relationship between response and toxicity.
Recent publications
Defining the genetic determinants of CD8+ T cell receptor repertoire in the context of immune checkpoint blockade.
Journal article
Ng ES. et al, (2025), Sci Adv, 11
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
Journal article
Milotay G. et al, (2025), Nat Med, 31, 2350 - 2364
Defining the genetic determinants of CD8 + T cell receptor repertoire in the context of immune checkpoint blockade
Preprint
Ng E. et al, (2024)